Results 141 to 150 of about 403,749 (266)

Identification of major congenital malformations based on healthcare databases in France: A proof‐of‐concept study using the epi‐meres nationwide mother–child register

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Besides registries, healthcare databases can provide useful information for assessing the frequency of major congenital malformations (MCMs) and investigating their risk factors, particularly medication exposures. This study aimed to assess the validity of MCMs identification based on French national, comprehensive healthcare databases ...
Tom Duchemin   +7 more
wiley   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu   +9 more
wiley   +1 more source

Leadless atrioventricular synchronous pacing in Eisenmenger syndrome

open access: yesHeartRhythm Case Reports, 2021
Paul Khairy, MD, PhD   +4 more
doaj   +1 more source

Descending aorta to right atrial fistula: Transcatheter embolization of a very rare anomaly with coils

open access: yesClinical Case Reports
Key Clinical Message Descending aorta to right atrial (RA) fistula is a rare and distinct clinical entity mimicking patent ductus arteriosus (PDA) and it may lead to rapid development of pulmonary vascular disease.
Stefanos Despotopoulos   +9 more
doaj   +1 more source

Transcatheter Repair of Sinus Venosus Defect Using a 12‐zig Covered Cheatham‐Platinum Stent in Large Superior Vena Cava—Right Atrium Junctions: Early Multicenter Experience

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Sinus venosus defect (SVD) is a rare congenital heart anomaly characterised by an abnormal communication between the atria, often associated with partial anomalous pulmonary venous connection (PAPVC). Traditional surgical repair carries significant risks, prompting exploration into less invasive transcatheter approaches.
Alberto Fuensalida   +7 more
wiley   +1 more source

Echocardiography‐Assisted Stenting of the Ductus Venosus in Infracardiac TAPVC: Report of a New Technique and Review of the Literature

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Neonates with infracardiac total anomalous pulmonary venous connection (TAPVC) frequently require urgent treatment. If surgical repair is contraindicated due to extreme prematurity, interventional stenting of the ductus venosus (DV) has been introduced successfully to postpone surgery.
Simon Schmid   +4 more
wiley   +1 more source

Single Centre Experience With the Balloon‐Expandable Myval Transcatheter Aortic Valve System in Patients With Bicuspid Anatomy: 1 Year Follow‐Up

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) anatomy remains challenging due to anatomical complexity and limited trial data. New‐generation balloon‐expandable valves, such as Myval, require further evaluation in this subgroup.
Balázs Magyari   +11 more
wiley   +1 more source

Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Very little research has been done on the possible effects that repeated, frequent, and low‐dose ionizing radiation exposure has on the long‐term health of interventional cardiologists. Aims Following the diagnosis in the same year of two central nervous system tumors in two operators working in the same catheter laboratory, we ...
James R. Bentham, John D. R. Thomson
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy